Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PLX9486 + Sunitinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLX9486 | PLX-9486|PLX 9486|Bezuclastinib|CGT-9486|CGT9486|CGT 9486 | KIT Inhibitor 57 | PLX9486 is a Kit inhibitor with selective activity against primary (exon 9 and 11) and secondary (exon 17 and 18) Kit mutations, which may lead to growth inhibition in tumor cells expressing mutant c-Kit (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509, PMID: 30523507). | |
Sunitinib | Sutent | SU011248 | CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 RET Inhibitor 53 VEGFR2 Inhibitor 37 | Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06208748 | Phase II | PLX9486 + Sunitinib | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | Recruiting | USA | 0 |
NCT05208047 | Phase III | Sunitinib PLX9486 + Sunitinib PLX9486 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Recruiting | USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS | ARG | 5 |
NCT02401815 | Phase Ib/II | PLX9486 + Sunitinib Pexidartinib + PLX9486 PLX9486 | PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors | Completed | USA | 0 |